The place of DPP-4 inhibitors in the treatment algorithm of diabetes type 2: a systematic review of cost-effectiveness studies (Q38983533)

8 September 2017

1 reference

title

The place of DPP-4 inhibitors in the treatment algorithm of diabetes type 2: a systematic review of cost-effectiveness studies (English)

1 reference

8 September 2017

Julian Perelman

5

0 references

author name string

Alexandre Baptista

1

1 reference

8 September 2017

Inês Teixeira

2

1 reference

8 September 2017

Sónia Romano

3

1 reference

8 September 2017

António Vaz Carneiro

4

1 reference

8 September 2017

17 October 2016

1 reference

The European Journal of Health Economics

8 September 2017

1 reference

https://scigraph.springernature.com/pub.10.1007/s10198-016-0837-7

8 September 2017

0 references

cites work

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS10198-016-0837-7

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-016-0837-7

Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-016-0837-7

Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-016-0837-7

Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-016-0837-7

Treatment of type 2 diabetes with saxagliptin: a pharmacoeconomic evaluation in Argentina

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-016-0837-7

Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff diabetes model analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-016-0837-7

Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-016-0837-7

Real-world clinical and economic outcomes of liraglutide versus sitagliptin in patients with type 2 diabetes mellitus in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-016-0837-7

Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-016-0837-7

Cost-Effectiveness Analysis of Incretin Therapy for Type 2 Diabetes in Spain: 1.8 mg Liraglutide Versus Sitagliptin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-016-0837-7

Incretin therapy for type 2 diabetes in Spain: a cost-effectiveness analysis of liraglutide versus sitagliptin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-016-0837-7

Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-016-0837-7

Cost-utility analysis of glucagon-like Peptide-1 agonists compared with dipeptidyl peptidase-4 inhibitors or neutral protamine hagedorn Basal insulin as add-on to metformin in type 2 diabetes in sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-016-0837-7

A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-016-0837-7

Computer modeling of diabetes and its complications: a report on the Fifth Mount Hood challenge meeting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-016-0837-7

Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-016-0837-7

Assessing the relationship between computational speed and precision: a case study comparing an interpreted versus compiled programming language using a stochastic simulation model in diabetes care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-016-0837-7

The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-016-0837-7

One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label tr

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-016-0837-7

Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-016-0837-7

Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-016-0837-7

Novel Therapeutics for Diabetes: Uptake, Usage Trends, and Comparative Effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-016-0837-7

Bias in published cost effectiveness studies: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-016-0837-7

Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-016-0837-7

Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagplitin

21 January 2018

1 reference

12 December 2020

Evaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States

1 reference

12 December 2020

The cost-effectiveness of saxagliptin versus NPH insulin when used in combination with other oral antidiabetes agents in the treatment of type 2 diabetes mellitus in Poland

1 reference

12 December 2020

Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis.

1 reference

12 December 2020

Cost-effectiveness of insulin glargine versus sitagliptin in insulin-naïve patients with type 2 diabetes mellitus

1 reference

12 December 2020

Cost-effectiveness and budget impact of saxagliptine as additional therapy to metformin for the treatment of diabetes mellitus type 2 in the Brazilian private health system

1 reference

12 December 2020

Development of a diabetes treatment simulation model: with application to assessing alternative treatment intensification strategies on survival and diabetes-related complications

1 reference

12 December 2020

Cost-effectiveness of saxagliptin (Onglyza®) in type 2 diabetes in Sweden

1 reference

12 December 2020

10.1007/S10198-016-0837-7

Identifiers

DOI

0 references

1 reference